Clinical commentary: the bromocriptine (Parlodel) controversy and recommendations for lactation suppression.
Mounting concerns about bromocriptine (Parlodel) and rare cardiovascular and cerebrovascular accidents have prompted the manufacturer to remove the drug from the market for use in postpartum lactation suppression. No drug is available now or will be in the forseeable future for the indication. This change in prescribing practice should alert the physician to counseling the expectant mother about the merits of breast feeding and about simple, non-pharmacologic methods of suppressing milk production.
Rayburn
W F
WF
Department of Obstetrics and Gynecology, University of Oklahoma, College of Medicine, Oklahoma City, USA.
D001942:Breast Feeding; D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000139:chemically induced; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007774:Lactation / Q000187:drug effects*; D049590:Postpartum Period; D012640:Seizures / Q000139:chemically induced; D014481:United States; D014486:United States Food and Drug Administration
D018491:Dopamine Agonists; D001971:Bromocriptine